TKI 258 Dovitinib Lactate C Kit Inhibitors Cas 915769-50-5
TKI 258 Dovitinib Lactate C Kit Inhibitors Cas 915769-50-5
+ AII PRODUCTS
- Prostaglandins - Custom Synthesis - PARP Inhibitors - PI3K Inhibitors - FAK Inhibitors - AKT Inhibitors - C-Kit Inhibitors - VEGFR Inhibitors - c-Met Inhibitors - CDK Inhibitors - CYP17 Inhibitors - DNA/RNA Inhibitors - mTOR Inhibitors - SRC Inhibitors - Others
Product
|
Size |
Price |
Stock |
Quantity |
|---|---|---|---|
|
Get Quotation Now Add to Cart Bulk Inquiry |
|||
AddThis Sharing Buttons
Share to FacebookFacebookShare to TwitterTwitterShare to PrintPrintShare to EmailEmailShare to PinterestPinterestShare to GmailGmailShare to LinkedInLinkedInShare to Email AppEmail AppShare to TumblrTumblrShare to MoreAddThis
Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.
Chemical Information
|
Product name:Dovitinib Lactate |
Purity:98% min |
|
CAS NO:915769-50-5 |
Solubility:DMSO: 25 mg/mL |
|
Molecular Formula:C24H29FN6O5 |
Package:Package according to customer requirements |
|
Molecular Weight:500.523 |
Storage:Store at -20℃ |
Quality control
Remarks
Dovitinib, also known as TKI-258 or CHIR-258, is an orally bioavailable FGFR3 inhibitor, which strongly binds to fibroblast growth factor receptor 3 (FGFR3) and inhibits its phosphorylation, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell death. In addition, this agent may inhibit other members of the RTK superfamily, including the vascular endothelial growth factor receptor; fibroblast growth factor receptor 1; platelet-derived growth factor receptor type 3; FMS-like tyrosine kinase 3; stem cell factor receptor (c-KIT); and colony-stimulating factor receptor 1; this may result in an additional reduction in cellular proliferation and angiogenesis, and the induction of tumor cell apoptosis.
Related Products
Pexidartinib hcl; Pexidartinib; Telatinib; Avapritinib; Amuvatinib; Linifanib; OSI-930; Crenolanib; Motesanib Diphosphate; Motesanib; Sunitinib; Imatinib mesylate; Axitinib; Masitinib; Dovitinib; ISCK03
References
-
[1] Trudel S, et al. Blood. 2005, 105(7), 2941-2948.
-
[2] Huynh H, et al. J Hepatol. 2012, 56(3), 595-601.
-
[3] Lee SH, et al. Clin Cancer Res. 2005, 11(10), 3633-3641.
Get in Touch
Have questions about our products or want to discuss a custom order? Our team is ready to help you.